Last updated on March 2018

Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery


Brief description of study

The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxifene (Duavee) causes any changes in the proliferation markers within the breast tissue of the study subjects. The study drug is approved by the US Food and Drug Administration in healthy postmenopausal women to treat certain symptoms of menopause such as hot flashes. Since it is not approved in women with DCIS, its use in this study is experimental. This study will also look at whether taking the study drug causes any significant or undesirable side effects in women with DCIS. The researchers hope that this study will help them determine if taking the study drug is safe in women taking DCIS and if it can possibly reduce the risk of developing breast cancer in women with DCIS.

Detailed Study Description

PRIMARY OBJECTIVES; I. To assess whether CE/BZA (conjugated estrogens/bazedoxifene) for 28 days +/- 7 days reduces proliferation as measured by marker of proliferation Ki-67 (Ki-67) protein expression.

SECONDARY OBJECTIVES:

I. To assess whether CE/BZA alters markers associated with progression to invasive cancer (abrogated response to cellular stress [ARCS] signature) in postmenopausal women with ductal carcinoma in situ [DCIS] compared to placebo).

II. To assess changes in quality of life (QOL) using the Menopause-specific Quality of Life (MENQOL) questionnaire at baseline and at the conclusion of the intervention in women with DCIS treated with CE/BZA compared to placebo.

TERTIARY OBJECTIVES:

I. To assess changes in the stromal marker cluster of differentiation (CD)36, in women with DCIS with CE/BZA compared to placebo.

II. To assess changes in hormone receptor (estrogen receptor alpha [ERa] and progesterone receptor [PR]) expression in women with DCIS treated with CE/BZA compared to placebo.

III. To assess changes in global gene expression profiling (ribonucleic acid [RNA] sequencing) in women with DCIS treated with CE/BZA compared to placebo.

IV. To identify possible polymorphisms that may affect the metabolism of CE/BZA.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive conjugated estrogens/bazedoxifene orally (PO) once daily (QD) on days 1-28 in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.

ARM II: Patients receive placebo PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.

After completion of study treatment, patients are followed up for 30 days.

Clinical Study Identifier: NCT02694809

Contact Investigators or Research Sites near you

Start Over

Julie E. Lang, MD, FACS

University of Southern California
Los Angeles, CA United States
  Connect »

Thea Tlsty, PhD

University of California
San Francisco, CA United States
  Connect »

Nimmi Kapoor, MD

Cancer Research Collaboration, Inc.
Santa Ana, CA United States
  Connect »

Swati A. Kulkarni, MD

Northwestern University
Chicago, IL United States
  Connect »

Nora Jaskowiak, M.D., FACS

University of Chicago
Chicago, IL United States
  Connect »

Tara M. Breslin, MD, FACS

Northwestern University
Lake Forest, IL United States
  Connect »

David M. Euhus, MD

John's Hopkins University
Baltimore, MD United States
  Connect »

Judy E. Garber, MD, MPH

Dana Farber/Partners Cancer Care Inc
Boston, MA United States
  Connect »

Rebecca Aft, MD, PhD

Washington University in St. Louis/ Siteman Cancer Center
Saint Louis, MO United States
  Connect »